Literature DB >> 8280490

HLA expression in pre-invasive cervical neoplasia in relation to human papilloma virus infection.

S S Glew, M E Connor, P J Snijders, C M Stanbridge, C H Buckley, J M Walboomers, C J Meijer, P L Stern.   

Abstract

A significant proportion of cervical carcinomas show loss of major histocompatibility complex human leucocyte antigen (HLA) class I expression while upregulating HLA class II expression. These changes may have direct consequences for immune surveillance of the human papilloma virus (HPV) infection which is strongly associated with cervical malignancy. A relationship between changes in HLA expression and HPV infection may be evident in the evolution of premalignant disease. This immunohistological study of 104 colposcopic biopsies establishes that HLA class II expression occurs in a significant proportion of squamous epithelia showing histological evidence of wart virus infection and cervical intraepithelial neoplasia (CIN) I to III. In comparison, alteration of HLA class I expression in cervical premalignant lesions is rare. There is no correlation between the detection of high risk HPV DNA (types 16, 18, 31 and 33) by polymerase chain reaction (PCR) and the MHC class II phenotype of the lesion. This suggests that altered HLA class II expression is neither a consequence nor a prerequisite for HPV infection.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8280490     DOI: 10.1016/0959-8049(93)90453-m

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  9 in total

1.  Classical HLA alleles are associated with prevalent and persistent cervical high-risk HPV infection in African women.

Authors:  Sally N Adebamowo; Adebowale A Adeyemo
Journal:  Hum Immunol       Date:  2019-05-06       Impact factor: 2.850

2.  Cathepsin E expression by normal and premalignant cervical epithelium.

Authors:  F Mota; J H Kanan; N Rayment; T Mould; A Singer; B M Chain
Journal:  Am J Pathol       Date:  1997-04       Impact factor: 4.307

3.  Differences of reactivity to interferon gamma in HeLa and CaSki cells: a combined immunocytochemical and flow-cytometric study.

Authors:  G Lizard; M C Chignol; Y Chardonnet; D Schmitt
Journal:  J Cancer Res Clin Oncol       Date:  1996       Impact factor: 4.553

Review 4.  Molecular events in uterine cervical cancer.

Authors:  S A Southern; C S Herrington
Journal:  Sex Transm Infect       Date:  1998-04       Impact factor: 3.519

5.  Enriched HLA-DQ3 phenotype and decreased class I major histocompatibility complex antigen expression in recurrent respiratory papillomatosis.

Authors:  V R Bonagura; F P Siegal; A L Abramson; F Santiago-Schwarz; M E O'Reilly; K Shah; D Drake; B M Steinberg
Journal:  Clin Diagn Lab Immunol       Date:  1994-05

6.  Concurrent Chemoradiotherapy Increases the Levels of Soluble Immune Checkpoint Proteins in Patients with Locally Advanced Cervical Cancer.

Authors:  Chao Liu; Xiaohui Li; Aijie Li; Wenxue Zou; Rui Huang; Xiaoyu Hu; Jinming Yu; Xiaoling Zhang; Jinbo Yue
Journal:  J Immunol Res       Date:  2022-04-04       Impact factor: 4.818

7.  Differences in MHC and TAP-1 expression in cervical cancer lymph node metastases as compared with the primary tumours.

Authors:  F V Cromme; P F van Bommel; J M Walboomers; M P Gallee; P L Stern; P Kenemans; T J Helmerhorst; M J Stukart; C J Meijer
Journal:  Br J Cancer       Date:  1994-06       Impact factor: 7.640

8.  Frequency of down-regulation of individual HLA-A and -B alleles in cervical carcinomas in relation to TAP-1 expression.

Authors:  P J Keating; F V Cromme; M Duggan-Keen; P J Snijders; J M Walboomers; R D Hunter; P A Dyer; P L Stern
Journal:  Br J Cancer       Date:  1995-08       Impact factor: 7.640

9.  HLA class I and II expression in oropharyngeal squamous cell carcinoma in relation to tumor HPV status and clinical outcome.

Authors:  Anders Näsman; Emilia Andersson; Linda Marklund; Nikolaos Tertipis; Lalle Hammarstedt-Nordenvall; Per Attner; Tommy Nyberg; Giuseppe V Masucci; Eva Munck-Wikland; Torbjörn Ramqvist; Tina Dalianis
Journal:  PLoS One       Date:  2013-10-10       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.